The potential role for GLP-1 receptor agonists in cancer survivorship: a narrative review
George Hatzis1, Audrey McKennitt1, Ben S Gerber1
1Department of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, 55 Lake Avenue North, Worcester, MA, 01655, United States.
Introduction:
Cancer survivors face a high burden of comorbidities which negatively influence long-term outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may augment these outcomes, but their role in this population remains understudied.
Methods:
We conducted a literature review of randomized controlled trials, observational studies, retrospective cohort studies, pre-clinical trials, and reviews related to GLP-1 RAs and cancer survivors.
Results:
We first delineate the GLP-1 RA mechanisms of action in glycemic control, inflammation, cardiovascular protection, neuroprotection, nephroprotection, and cancer proliferation. Then, we highlight the potential clinical benefits that these drugs could have in cancer survivors based on available studies, including metabolism, cardiovascular risk, lymphedema and mortality. Finally, we address ongoing safety concerns for GLP-1 RAs, particularly focusing on their potential use in cancer survivors.
Discussion:
Given the limited evidence to date, further research is needed to evaluate the long-term benefits and safety of GLP-1 RA use in cancer survivors.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
01:21Cancer Survival Analysis
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...